Glasgow’s life sciences community is expanding in part because of the efforts of The Living Laboratory of Precision Medicine.
The laboratory is a consortium which brings together industry, NHS Scotland and the University of Glasgow and is funded through consortium partners and government body the UKRI (UK Research and Innovation).
“We’re using some of the funding that we got to create and to expand the infrastructure for companies,” said Carol Clugston, Dean of Corporate Engagement & Innovation and Chief Operating Officer, University of Glasgow.
“We’ve got a really attractive campus which is centred around the Queen Elizabeth University Hospital in Glasgow, which is the biggest hospital in the UK.”
“But it’s not just about the hard infrastructure, it’s about how we can support companies to engage with clinicians to engage with the NHS,” she added.
Clugston explained to Real Asset Insight’s Richard Betts that the benefits that the Living Laboratory is seeking range from the obvious, things like patient benefit, to supporting the NHS in Scotland, reducing the cost of healthcare and creating assets for research and healthcare.
“But one of the important drivers through this funding program is really to support productivity growth in in Glasgow.”